Physician profile
Amy Guan
NPI 1801398813
$4,872.06
in general payments reported to CMS, 2019-2025
32 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $475 · 2024: $2,271 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,872.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $811.95 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $801.61 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $567.38 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $374.36 | 2023-2025 | Evenity, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $357.26 | 2023-2025 | Rexulti |
| Abbvie INC. | $254.98 | 2024-2025 | |
| Lundbeck LLC | $218.99 | 2024-2025 | Rexulti |
| Pfizer INC. | $204.64 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $123.79 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $116.34 | 2024-2025 | |
| Glaxosmithkline, LLC. | $103.70 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.69 | 2023-2025 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $98.68 | 2024 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $79.68 | 2023-2024 | Auvelity |
| Valinor Pharma, LLC | $67.83 | 2024-2025 | Movantik |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $66.36 | 2023-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $66.13 | 2024-2025 | Voquezna |
| Mannkind Corporation | $57.54 | 2023-2024 | Afrezza |
| Vanda Pharmaceuticals INC. | $50.57 | 2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $50.52 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.11 | 2024 | Eliquis |
| Corcept Therapeutics | $39.01 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $34.03 | 2023 | Belsomra |
| Exact Sciences Corporation | $31.81 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $22.36 | 2025 | Inspire |
| Nestle Healthcare Nutrition INC. | $21.69 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.25 | 2024 | Caplyta |
| Tris Pharma INC | $17.62 | 2024 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.43 | 2025 | Jardiance |
| Eisai INC. | $16.65 | 2024 | |
| Corium, LLC | $15.75 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $13.35 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Guan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.